Aster Capital Management (Difc) LTD Phathom Pharmaceuticals, Inc. Transaction History
Aster Capital Management (Difc) LTD
- $262 Billion
- Q4 2024
A detailed history of Aster Capital Management (Difc) LTD transactions in Phathom Pharmaceuticals, Inc. stock. As of the latest transaction made, Aster Capital Management (Difc) LTD holds 15 shares of PHAT stock, worth $83. This represents 0.0% of its overall portfolio holdings.
Number of Shares
15
Previous 45
66.67%
Holding current value
$83
Previous $814,000
85.01%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding PHAT
# of Institutions
158Shares Held
68.6MCall Options Held
52.3KPut Options Held
635K-
Frazier Life Sciences Management, L.P. Menlo Park, CA10.1MShares$56 Million4.92% of portfolio
-
Medicxi Ventures Management (Jersey) LTD7.46MShares$41.4 Million13.31% of portfolio
-
Jennison Associates LLC7.06MShares$39.1 Million0.04% of portfolio
-
Invesco Ltd. Atlanta, GA3.67MShares$20.3 Million0.01% of portfolio
-
Carlyle Group Inc. Washington, DC3.5MShares$19.4 Million28.4% of portfolio
About Phathom Pharmaceuticals, Inc.
- Ticker PHAT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,175,200
- Market Cap $217M
- Description
- Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...